Navigation Links
Honeywell Signs Supply Agreement with Chinese Company for Aclar(R) Film

Agreement with Haishun will help meet increasing demand for pharmaceutical packaging in China

SHANGHAI, China, Nov. 6 /PRNewswire/ -- Honeywell (NYSE: HON) announced today that it has signed a three-year supply agreement with Shanghai Haishun Packaging Material Co., Ltd., to provide the Chinese company with Honeywell's Aclar(R) brand moisture-barrier films for pharmaceutical packaging.

Honeywell will also provide technical services and training to Haishun as part of the agreement.

"We continue to focus on meeting the current and future packaging needs of the pharmaceutical industry for packaging materials which protect their products," said Rick Knight, global business manager for Honeywell's Heath Care and Packaging business. "Our supply agreement with Haishun will allow us to better serve our customers in the Chinese market."

Honeywell and Haishun are partnering to meet the steady and rapidly growing demand for pharmaceutical packaging in China. According to IMS Health, a pharmaceutical and health care market intelligence company, China is the largest and fastest growing market within the Asia-Pacific region for the pharmaceutical industry. In 2007, the Chinese pharmaceutical market recorded sales of $19 billion with annual growth of 26 percent.

"Honeywell has years of experience in technology innovation and offers market advantages in the area of specialty films," said Weir Lin, general manager of Haishun. "Our agreement with Honeywell will upgrade the technology and quality level of our products, and allow us to promote new moisture-barrier packing materials to pharmaceutical manufacturers in China."

To support the growing needs of its customers in China and the Asia-Pacific region, Honeywell Specialty Materials opened its Asia-Pacific Technology Center in Shanghai's Zhangjiang Hi-tech Park in late 2004. One of the major areas of research conducted at the 56,000-square-foot (5,200-square-meter) Technology Center is specialty films.

Aclar polychlorotrifluoroethylene (PCTFE) fluoropolymer films have excellent moisture barrier and chemical stability properties. Aclar films are crystal clear, biochemically inert, chemical-resistant, nonflammable, and plasticizer- and stabilizer-free. The Aclar supplied to Haishun will be produced at Honeywell's plant in Pottsville, Pa., in the United States.

In addition to Aclar, Honeywell manufactures Burdick & Jackson(R) high-purity solvents and DNA and RNA reagents and Oxyfume(R) gases used to sterilize heat-sensitive medical devices.

Shanghai Haishun Packaging Material Co., Ltd. is based in Shanghai and is a leading packaging materials supplier for the pharmaceutical industry in China. The company's production facilities have received Good Manufacturing Practices (GMP) certification from the Chinese government, and all its products are duly registered as national pharmaceutical packaging materials.

Honeywell Specialty Materials, based in Morristown, N.J., is a $4.9 billion, global leader in providing customers with high-performance specialty materials, including fluorine products; specialty films and additives; advanced fibers and composites; intermediates; specialty chemicals; electronic materials and chemicals; and technologies and materials for petroleum refining.

Honeywell International is a $38 billion diversified technology and manufacturing leader, serving customers worldwide with aerospace products and services; control technologies for buildings, homes and industry; automotive products; turbochargers; specialty chemicals; fibers; and electronic and advanced materials. Based in Morris Township, NJ, Honeywell's shares are traded on the New York, London, Chicago and Pacific Stock Exchanges. It is a component of the Standard & Poor's 500 Index. For additional information, please visit

This report contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of fact, that address activities, events or developments that we or our management intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Forward-looking statements are based on management's assumptions and assessments in light of past experience and trends, current conditions, expected future developments and other relevant factors. They are not guarantees of future performance, and actual results, developments and business decisions may differ from those envisaged by our forward-looking statements. Our forward-looking statements are also subject to risks and uncertainties, which can affect our performance in both the near- and long-term. We identify the principal risks and uncertainties that affect our performance in our Form 10-K and other filings with the Securities and Exchange Commission.

SOURCE Honeywell
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Honeywell Expands Aclar(R) Production for Pharmaceutical Industry
2. Spot the Warning Signs of Cancer in Your Pet
3. NeoStem Signs Definitive Agreement to Acquire Controlling Interest in a Leading Chinese Pharmaceutical Company
4. Gateway Health Plan(R) Signs New Agreement with Cleveland Clinic Hospitals
5. LifeSync Corporation Signs MAGNET Contract
6. Wayport Signs Agreement with Sun Healthcare Group to Enable Public Internet Access : Sun's Inpatient Services Subsidiaries to Utilize Public Applications Managed by Wayport
7. Designs for Health Acquires eHealthPro™ and eNatro™ Practice Management Software
8. ACS Signs $27 Million Contract with Alaska to Transition Fiscal Agent Services for State Medicaid Program
9. Avidas Pharmaceuticals Signs Agreement to Acquire North American Rights to Products That Address Chronic Dermatologic Conditions
10. 2nd International Conference, Signs of Autism in Infants: Changing Outcomes Through Early Identification and Intervention, October 11 & 12, 2008; Unique and Critical Event
11. LodgeNet Healthcare Signs New Agreement with NorthShore University HealthSystem
Post Your Comments:
(Date:11/25/2015)... ... November 26, 2015 , ... ... (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and public R&D ... Nairobi (UNON) for the opening of the 5th African Network for Drugs and ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is ... One Beat ” campaign. The partnership between the two groups began in 2014 with ... International’s cause. , MAP International was founded in 1954 and is an international Christian-based ...
(Date:11/25/2015)... ... 2015 , ... Lakeview Health, a Jacksonville-based drug and alcohol ... and show through pictures what a positive difference it makes. The social media ... hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. Short stories can ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law ... successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys ... Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
(Date:11/25/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a developer ... Officer Antonius Schuh, Ph.D., is scheduled to present a ... Jaffray Healthcare Conference. th Annual Piper ... in New York on Tuesday, ... will be available for one-on-one meetings during the conference. ...
(Date:11/25/2015)... , November 25, 2015 ... self-monitoring blood glucose devices was valued at $11,171.1 million ... a CAGR of 5.7% during 2015 - 2022. The ... and increasing prevalence of diabetes. In addition, the increase ... is also contributing to the growth of the market. ...
Breaking Medicine Technology: